Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRN-119 Alone and With Decitabine in TP53-Mutated AML or HR-MDS
NCT07617363Phase 1Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATRN-119 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Washington University School of Medicine. Primary endpoints: Treatment-Emergent Adverse Events at 23 months and Dose-Limiting Toxicities. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ATRN-119
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07617363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617363.